It also discusses metastatic renal cell carcinoma – a global scourge with an extremely poor long-term survival prognosis, the course and sequelae of renal cell carcinoma, as well as advances in targeted molecular therapy with sunitinib, a receptor tyrosine kinase inhibitor.
